Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Therapeutic Innovation & Regulatory Science
|
September 20, 2018
Benchmarking the Study Initiation Process
Mary Jo Lamberti, Cindy Brothers, Dan Manak, et al.
Pharmaceutical Statistics
|
May 31, 2007
PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events
Sara Hughes, Arlene Hughes, Cindy Brothers, et al.
Lancet (London, England)
|
April 5, 2008
Abacavir and the potential risk of myocardial infarction
Amy Cutrell, Cindy Brothers, Jane Yeo, et al.
Journal of Clinical Pharmacology
|
September 5, 2024
A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1
Hardik Chandasana, Ann M Buchanan, Michael McKenna, et al.
The Pediatric Infectious Disease Journal
|
November 24, 2021
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children
Rajendra P Singh, Kimberly K Adkison, Mark Baker, et al.
International Journal of Antimicrobial Agents
|
August 15, 2024
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective
Ann M Buchanan, Adrie Bekker, Hardik Chandasana, et al.
The Lancet. Infectious Diseases
|
October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen, Franco Maggiolo, José R Arribas, et al.
The Pediatric Infectious Disease Journal
|
February 4, 2026
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance
Hardik Chandasana, Ann M Buchanan, Cassidy A Henegar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2008
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients
Michael Saag, Rukmini Balu, Elizabeth Phillips, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Therapeutic Innovation & Regulatory Science
|
September 20, 2018
Benchmarking the Study Initiation Process
Mary Jo Lamberti, Cindy Brothers, Dan Manak, et al.
Pharmaceutical Statistics
|
May 31, 2007
PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events
Sara Hughes, Arlene Hughes, Cindy Brothers, et al.
Lancet (London, England)
|
April 5, 2008
Abacavir and the potential risk of myocardial infarction
Amy Cutrell, Cindy Brothers, Jane Yeo, et al.
Journal of Clinical Pharmacology
|
September 5, 2024
A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1
Hardik Chandasana, Ann M Buchanan, Michael McKenna, et al.
The Pediatric Infectious Disease Journal
|
November 24, 2021
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children
Rajendra P Singh, Kimberly K Adkison, Mark Baker, et al.
International Journal of Antimicrobial Agents
|
August 15, 2024
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective
Ann M Buchanan, Adrie Bekker, Hardik Chandasana, et al.
The Lancet. Infectious Diseases
|
October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen, Franco Maggiolo, José R Arribas, et al.
The Pediatric Infectious Disease Journal
|
February 4, 2026
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance
Hardik Chandasana, Ann M Buchanan, Cassidy A Henegar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2008
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients
Michael Saag, Rukmini Balu, Elizabeth Phillips, et al.
Page
of 1